|1.||Laquerre, Sylvie: 2 articles (12/2011 - 07/2010)|
|2.||Gilmartin, Aidan G: 2 articles (07/2010 - 09/2009)|
|3.||Yim, Hyungshin: 1 article (11/2013)|
|4.||Woditschka, Stephan: 1 article (12/2011)|
|5.||Brogi, Edi: 1 article (12/2011)|
|6.||Degenhardt, Yan Y: 1 article (12/2011)|
|7.||Meltzer, Paul S: 1 article (12/2011)|
|8.||Killian, J Keith: 1 article (12/2011)|
|9.||Skordos, Konstantine W: 1 article (12/2011)|
|10.||Lampkin, Thomas A: 1 article (12/2011)|
12/01/2011 - "GSK461364A sensitized tumor cells to radiation induced cell death in vitro. "
07/01/2010 - "As many cancer therapies tend to be more effective in p53 WT patients, the higher sensitivity of p53-deficient tumors toward GSK461364A could potentially offer an opportunity to treat tumors that are refractory to other chemotherapies as well as early line therapy for these genotypes."
09/01/2009 - "Cell culture growth inhibition by GSK461364A can be cytostatic or cytotoxic but leads to tumor regression in xenograft tumor models under proper dose scheduling. "
07/01/2010 - "Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability."
09/01/2009 - "Finally, we describe pharmacodynamic biomarkers of GSK461364A activity (pHH3 and Plk1) that are currently being evaluated in human cancer clinical trials."
|2.||Breast Neoplasms (Breast Cancer)
|4.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
07/01/2009 - "Presentation highlights from the Kinase Inhibitor 4 Minisymposium include the identification of FGF receptor genetic alterations that correlate with sensitivity to the kinase inhibitor TKI258; evaluation of activity of mitotic kinase inhibitors GSK461364A and AZD1152 in breast and small-cell lung cancer and the identification of new inhibitors to PI3K/AKT/mTOR pathway."
|5.||Chromosomal Instability (Chromosome Stability)
|1.||Biological Markers (Surrogate Marker)
|2.||Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)
|4.||Adenosine Triphosphate (ATP)
|5.||2- ((3- ((4- ((5- (2- ((3- fluorophenyl)amino)- 2- oxoethyl)- 1H- pyrazol- 3- yl)amino)quinazolin- 7- yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
|7.||4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- one
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)